CWBR - コ―バ― （CohBar Inc.） コ―バ―CWBRのチャート
CWBRの企業情報
| symbol | CWBR |
|---|---|
| 会社名 | CohBar Inc （コ―バ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 CohBar Inc. (CohBar) is engaged in the research and development of mitochondria-based therapeutics (MBTs) a class of drugs with potential for the treatment of diseases associated with aging. MBTs originate from the discovery of a group of peptides encoded within the genome of mitochondria. The Company's development of mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a range of diseases including type 2 diabetes cancer atherosclerosis and neurodegenerative disorders. MDPs represent a diverse and largely unexplored collection of peptides. MOTS-c is an MDP which indicates that it plays a role in the regulation of metabolism. The Company is engaged in the research on MOTS-c and its analogs as its lead program. The Company's academic collaborators have discovered various other MDPs with similar mitochondrial origin to the MDP humanin which the Company refers to as small humanin-like peptides (SHLPs). コ―バ―は米国のバイオ医薬品企業。主に2型糖尿病の治療薬の研究開発に従事する。肥満、脂肪肝疾患、脂肪性肝炎など老化および代謝機能不全に関連する疾患に対する、ミトコンドリアベ―スの治療薬を手掛ける。また、同社はがん、アテロ―ム性動脈硬化症、心臓血管疾患、アルツハイマ―病の治療薬も開発する。本社所在地はカリフォルニア州メンロパ―ク。 CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases because of the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has 4 preclinical programs: CB5138 Analogs for fibrotic diseases, CB5064 Analogs for COVID-19 associated ARDS, MBT5 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy. |
| 本社所在地 | 1455 Adams Drive Suite 2050 Menlo Park CA 94025 USA |
| 代表者氏名 | Albion J. Fitzgerald アルビオンJ.フィッツジェラルド |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-446-7888 |
| 設立年月日 | 40057 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cohbar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cwbr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.39973 |
| 終値（lastsale） | 4.015 |
| 時価総額（marketcap） | 170492140.94 |
| 時価総額 | 時価総額（百万ドル） 163.06100 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 137.73505 |
| 当期純利益 | 当期純利益（百万ドル） -12.59721 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CohBar Inc revenues was not reported. Net loss increased 67% to $6.9M. Higher net loss reflects Research and development increase of 76% to $4.5M (expense) General and administrative increase of 41% to $2.2M (expense) Amortization of debt discount and offeri increase from $0K to $105K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.17. |
CWBRのテクニカル分析
CWBRのニュース
Up to Date Stock in scrutiny: CohBar, Inc. (NASDAQ:CWBR), Globalstar, Inc. (AMEX:GSAT) 2021/06/22 20:44:30 Stock Equity
CohBar, Inc. (NASDAQ:CWBR) with the stream of -9.78% also noticed, India Globalstar, Inc. (AMEX:GSAT) encountered a rapid change of 19.21% in the last hour of Tuesdays trading session. CohBar, Inc. The post Up to Date Stock in scrutiny: CohBar, Inc. (NASDAQ:CWBR), Globalstar, Inc. (AMEX:GSAT) appeared first on Stocks Equity .
CohBar to Present at the BIO 2021 Digital Conference 2021/06/10 13:00:00 Intrado Digital Media
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced its Chief Executive Officer Dr. Joseph Sarret will present a corporate overview at the BIO 2021 Digital Conference, to be held on June 14 - 18, 2021. This presentation will be available on demand for registered attendees.
Cohbar Inc (CWBR) falls 1.43% for May 19 2021/05/19 22:00:30 Equities
Cohbar Inc (NASDAQ: CWBR) shares fell -1.43% to end trading Wednesday at $1.38 per share - a net change of $-0.02. Shares traded between $1.45 and $1.32 throughout the day. 322240 shares of Cohbar Inc exchanged hands. Visit Cohbar Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Cohbar Inc and to follow the companys latest updates, you can visit the companys profile page here: Cohbar Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.
Maxim Group Gives a Buy Rating to CohBar (CWBR) 2021/05/19 12:25:59 Smarter Analyst
Maxim Group analyst Jason McCarthy assigned a Buy rating to CohBar (CWBR) yesterday and set a price target of $3.00. The post Maxim Group Gives a Buy Rating to CohBar (CWBR) appeared first on Smarter Analyst .
CohBar (CWBR) Gets a Buy Rating from Chardan Capital 2021/05/18 11:46:01 Smarter Analyst
In a report released today, Michael Morabito from Chardan Capital reiterated a Buy rating on CohBar (CWBR). The companys shares closed last Monday The post CohBar (CWBR) Gets a Buy Rating from Chardan Capital appeared first on Smarter Analyst .
EFFECT - CohBar, Inc. (0001522602) (Filer) - Stocks News Feed 2021/02/01 05:15:37 Stocks News Feed
Accepted 2021-02-01 00:15:37 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2021-01-29 Registration Form S-3 Document Format Files Mailing Address 1455 ADAMS DRIVE, SUITE 2050 MENLO BUSINESS PARK MENLO PARK CA 94025 Business Address 1455 ADAMS DRIVE, SUITE 2050 MENLO BUSINESS PARK MENLO PARK CA… Read More »EFFECT – CohBar, Inc. (0001522602) (Filer)
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 2020/07/30 13:00:00 GlobeNewswire
Company to host conference call and webcast at 5:00 p.m. ET
CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript 2019/05/10 22:56:29 Seeking Alpha
EFFECT - CohBar, Inc. (0001522602) (Filer) - Stocks News Feed 2021/02/01 05:15:37 Stocks News Feed
Accepted 2021-02-01 00:15:37 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2021-01-29 Registration Form S-3 Document Format Files Mailing Address 1455 ADAMS DRIVE, SUITE 2050 MENLO BUSINESS PARK MENLO PARK CA 94025 Business Address 1455 ADAMS DRIVE, SUITE 2050 MENLO BUSINESS PARK MENLO PARK CA… Read More »EFFECT – CohBar, Inc. (0001522602) (Filer)
CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 2020/07/30 13:00:00 GlobeNewswire
Company to host conference call and webcast at 5:00 p.m. ET